

URGENT DRUG RECALL Metoclopramide Tablets USP 10mg May 23, 2025

Teva Pharmaceuticals USA, Inc.

| Metoclopramide Tablets USP 10mg | | | | | | | |
|---------------------------------|---------|-----------|------------------|--|--|--|--|
| NDC | Lot# | Exp. Date | Size | | | | |
| 0093-2203-01 | 5420094 | 09/2027 | 100 count bottle | | | | |

Dear Valued Customer:

Teva Pharmaceuticals USA, Inc. (TEVA) is initiating a voluntary nationwide recall of <u>the above one (1) lot</u> of Metoclopramide Tablets USP 10 mg to the CONSUMER LEVEL. The product in this recall is distributed under the Teva Pharmaceuticals USA, Inc. label. This lot is being recalled as a safety precaution because, to date, a single Torsemide Tablet (20 mg) was discovered in each of three individual sealed bottles of Metoclopramide Tablets USP, 10 mg lot 5420094. The clinical concern regarding use of the recalled lot is lack of effect or lack of efficacy and/or potential for an adverse event(s). To date, TEVA has received no relevant complaints for drug ineffectiveness, lack of effect or lack of efficacy. Teva's health hazard assessment concluded that use of the subject product lot of concern could potentially lead to severe adverse health consequences outside the known safety profile of Metoclopramide if a Torsemide Tablet (20mg) is ingested, although the likelihood of occurrence is remote/unlikely as Metoclopramide Tablets are dispensed from the original packaging, divided at pharmacy level and dispensed in smaller quantities for patient use, where the difference in tablets is likely to be noticed by the pharmacist.

This recall is being made with the knowledge of the U.S. Food and Drug Administration.

Please take the following actions upon receipt of this letter:

- Immediately examine your inventory for Metoclopramide Tablets USP, 10 mg lot # 5420094.
- Immediately discontinue distribution of and guarantine Metoclopramide Tablets USP, 10 mg lot # 5420094 being recalled.
- TEVA's records indicate that the recalled lot was commercially distributed/shipped to its direct customers from 12/16/2024 through 01/27/2025.
- If you have further distributed Metoclopramide Tablets, USP 10 mg lot # 5420094, please perform a SUB-RECALL to your sub-accounts using this Recall Notification and Business Reply Form (BRF) as a basis for your recall notification.
- Promptly complete the attached Recall BRF, even if you have <u>no</u> product to return, and return the completed Recall BRF in its entirety to Inmar, Attn: Recall Coordinator by any one of these means:

MAIL: Inmar, One West Fourth Street, Suite 500, Winston Salem, NC 27101

EMAIL: <u>rxrecalls@inmar.com</u>. FAX: 817-868-5362

After receipt of your Recall BRF, Inmar will send labels for your Return Goods Authorization (RGA) and shipping of your product return. Products returned that are not the subject of the recall will not be credited and will be destroyed.

CONTACT INFORMATION AND CREDIT

Product Returns:

Contact Inmar at 855-243-4880 (Hours of Operation: M – F, 9.00 am to 5.00 pm Eastern Time) for Recall Stock Response forms or acquire from clsnetlink.com

Medical-related Questions or to report an Adverse Event:

Contact Teva Medical Information at: 888-838-2872, option 3, then option 4

Live calls received: M - F, 8:30 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week or by email at druginfo@tevapharm.com

Product Quality Complaint-related Questions:

Contact Teva Quality Assurance Services: 888-838-2872, option 4

Live calls received: M - F, 9:00 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week or by email at QAS.QAS@tevapharm.com

Customer Service-related Questions:

Contact Teva Customer Service: 888-838-2872, option 3, then option 2

Live calls received: M - F, 9:00 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week

FDA contact information for reporting adverse events/quality complaints:

Online at www.fda.gov/medwatch/report.htm or call FDA at 1-800-FDA-1088

Sincerely,

Regulatory Compliance, Teva Pharmaceuticals USA, Inc.



URGENT DRUG RECALL Metoclopramide Tablets USP 10mg May 23, 2025

Teva Pharmaceuticals USA, Inc.

RECALL BUSINESS REPLY FORM

| | Completed | ···· | | | | | | |
|---|--|--|--|--|--|------------------------------------|--|--|
| Fill out this fo | | | | _ | its entirety, it will delay the in the interest in the interes | ssuance of credit. Promptly return | | |
| | - | | | | | FAX: 817-868-5362 | | |
| MAIL: Inmar, 1 W 4th St., Winston Salem, NC 27101 EMAIL: rxrecalls@inmar.com FAX: 817-868-5362 Section 1 – Customer Information | | | | | | | | |
| This Stock Respo | onse is for (Check (| One): | | | | | | |
| ☐ Teva Direct Account | | | | | Non-Direct Customer | | | |
| Customer/Store Name: | | | | | Address (Street/City/State/Zip) | | | |
| | | | | | | | | |
| *DEA #: | | | | | *Debit Memo # | | | |
| *DEA # is required; in order to process your form. | | | | *Debit Memo # is required | *Debit Memo # is required; in order to process your form. | | | |
| Contact Name (please print): | | | | | Telephone #: | Telephone #: | | |
| | | | | | | | | |
| Please mark y | our answer - I have | checked my sto | ck and: | | • | | | |
| I <u>do</u> have stock of the recalled item(s) (complete section 2) OR I <u>do</u> not have stock of the recalled item(s). | | | | | | | | |
| Teva Direct Acc | | ed item(5) (comp | Acte Section | <i>2)</i> | 1 <u>do</u> nochav | e stock of the recalled rectings). | | |
| Does y | our response includ | le all your DC loo | ations? | |] YES | | | |
| Did yo | u communicate the | recalls to your d | irect account | :s | YES NO | | | |
| Non-Direct Cus | stomer | | | | | | | |
| | oduct(s) in this reca | ll were purchase | d from: | | | | | |
| | | | | Name of Yo | our Wholesaler/Distributor and | Location | | |
| Section 2 – Qu | antity of Product to | o Return | | | | | | |
| Enter the inform form. | ation of the recalle | d product(s) to l | be returned i | n the table b | elow. If additional space is ne | eded, please make copies of this | | |
| ioiii. | NDC# | | | Bottle | Quantity of Product | to Return | | |
| | NDC # | Lot# | Exp Date | Size | (Count Partial Bott | | | |
| | 0093-2203-01 | 5420094 | 09/2027 | 100 | | | | |
| Image Shown Has Not Been Reproduced to Scale of Actual Label | | | | | | | | |
| □ = | | | | | | | | |
| | | arsippary, | Emperature; Dispense in a tight, light resistant container. PROTECT ROM LIGHT. REFOTHS AND ALL MEDIATIONS OUT OF THE REAGH OF CHILDREN. Hauffactured in Croatia By. PLUM HRANTSKA doo. Zagreb, Croatia | Gech tablet contains metodopamide lydochloride USP equivalent to 10 mg metocopramide. Usual boxage: See package insert for full prescribing information. Store a 25° (68° to 77°F) See USP Controlled Room | Metoclopramide Tablets, USP 10 mg | | | |
| | | nufactured for: a Pharmaceutica is sippary, NJ 07054 | a tight, lig ROM UGH NID ALL M EREACH O ed in Croat TISKA do.a | tablet ontains clopramide hydroth alent to greecology metoclopramide. Dosage: See pack II prescribing infom III prescribing info | Tablets, USP | | | |
| | | 3-0 | th-resistal T. EDICATION F CHILDRE ia By | tablet contains (dopramide hy drodhoride USP alient to g metoc byramide. Dosage: See parkage insert If prescribing information at 20° to 25°C (68° to 77°F) 20°C (68° to 77°F) | FHARITACIST. DEPENSE THE | | | |
| | コープ 単の 第二 第 accompanying Medication Guide to each patient. | | | | | | | |
| | | Serialization Coding Area | | | Rx only 100 Tablets | | | |
| | | | | | | | | |
| Please indicate the number of shipping labels that you need to return the recalled product(s): | | | | | | | | |
| | | | | | | | | |
| Inmar/MedTur | | _abels | | ore | Kit | D.B | | |
| Scan | Į. | -anera | 51 | .016 | NIL | U.D | | |